All In Biotech

Investigational drug · Phase 2

QL2401

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metabolic Dysfunction-associated Steatohepatitis (MASH).

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "QL2401"

First trial start

2026

Dec 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "QL2401", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "QL2401" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Metabolic Dysfunction-associated Steatohepatitis (MASH)

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • IBI362Phase 38 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea

  • PemvidutidePhase 34 trials

    Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)

  • HRS-4729Phase 23 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.